MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Charles River Laboratories International Total Current Liabilities 2011-2026 | CRL
Annual Total Current Liabilities Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.12 B | 994 M | 1.06 B | 1.09 B | 1.03 B | 840 M | 710 M | 558 M | 464 M | 430 M | 312 M | 296 M | 247 M | 342 M | 217 M | 260 M | 250 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | 217 M | 601 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 203.06 | -0.38 % | $ 22.5 B | USA |
 |
Celcuity
CELC
|
44.2 M | $ 88.55 | -1.05 % | $ 4.14 B | USA |
 |
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
3.54 M | $ 4.29 | -8.72 % | $ 5.71 M | USA |
 |
Fulgent Genetics
FLGT
|
85 M | $ 18.68 | -0.53 % | $ 575 M | USA |
 |
Castle Biosciences
CSTL
|
68.7 M | $ 20.7 | -1.48 % | $ 600 M | USA |
 |
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
31.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.2 B | $ 146.18 | -2.49 % | $ 11.5 B |  Irlanda |
 |
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
303 M | $ 131.62 | 0.55 % | $ 16.5 B | USA |
 |
CareDx, Inc
CDNA
|
89.8 M | $ 22.97 | -2.92 % | $ 1.22 B | USA |
 |
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.05 M | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
5.1 M | $ 1.6 | -3.03 % | $ 7.08 M | USA |
 |
Illumina
ILMN
|
1.58 B | $ 160.97 | -3.15 % | $ 25 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M |  China |
 |
National Research Corporation
NRC
|
36.6 M | $ 18.79 | - | $ 421 M | USA |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Natera
NTRA
|
441 M | $ 212.07 | -3.27 % | $ 29 B | USA |
 |
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.31 | -2.96 % | $ 393 M | USA |
 |
Lantheus Holdings
LNTH
|
333 M | $ 104.52 | 0.19 % | $ 7.05 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
1.34 B | $ 467.34 | -1.63 % | $ 13.5 B | USA |
 |
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | USA |
 |
Mettler-Toledo International
MTD
|
1.2 B | $ 1 131.49 | -0.86 % | $ 23.3 B |  Schweiz |
 |
NeoGenomics
NEO
|
88.3 M | $ 11.15 | -2.79 % | $ 1.43 B | USA |
 |
Myriad Genetics
MYGN
|
134 M | $ 4.33 | -6.48 % | $ 401 M | USA |
 |
Personalis
PSNL
|
39.6 M | $ 9.59 | 1.8 % | $ 856 M | USA |
 |
Twist Bioscience Corporation
TWST
|
91.4 M | $ 76.17 | 2.86 % | $ 4.56 B | USA |
 |
Senseonics Holdings
SENS
|
24.3 M | $ 7.18 | -2.05 % | $ 300 M | USA |
 |
QIAGEN N.V.
QGEN
|
512 M | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
61.4 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.74 M | $ 2.05 | -1.91 % | $ 4.71 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 266.16 | 0.34 % | $ 22.1 B | USA |
 |
Thermo Fisher Scientific
TMO
|
15.2 B | $ 469.34 | -1.33 % | $ 177 B | USA |
 |
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
174 M | $ 9.1 | -1.57 % | $ 1.97 B | USA |
 |
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | USA |